Tryptamine Therapeutics Raises AU$6.1 Million to Advance TRP-8803 Clinical Development
Tryptamine Therapeutics Limited (ASX: TYP) has secured AU$6.1 million through a placement to accelerate the development of its TRP-8803 IV-infused psilocin formulation for neuropsychiatric disorders. The raise involved issuing 179.4 million shares at AU$0.034 each, with strong support from existing investors, including co-founder Dr. William Garner, who contributed AU$572,000, and board members who added AU$470,000.
Funds will fast-track the world-first Binge Eating Disorder trial with Swinburne University, support additional clinical programs, and advance manufacturing and regulatory readiness. CEO Jason Carroll said the raise strengthens Tryp’s balance sheet and enables progress across multiple indications, including trials in fibromyalgia and irritable bowel syndrome. Chairman Herwig Janssen noted that the strong investor response reflects growing confidence in the company’s clinical and commercial strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Tryptamine Therapeutics Raises AU$6.1 Million to Advance TRP-8803 Clinical Development
Tryptamine Therapeutics Limited (ASX: TYP) has secured AU$6.1 million through a placement to accelerate the development of its TRP-8803 IV-infused psilocin formulation for neuropsychiatric disorders. The raise involved issuing 179.4 million shares at AU$0.034 each, with strong support from existing investors, including co-founder Dr. William Garner, who contributed AU$572,000, and board members who added AU$470,000.
Funds will fast-track the world-first Binge Eating Disorder trial with Swinburne University, support additional clinical programs, and advance manufacturing and regulatory readiness. CEO Jason Carroll said the raise strengthens Tryp’s balance sheet and enables progress across multiple indications, including trials in fibromyalgia and irritable bowel syndrome. Chairman Herwig Janssen noted that the strong investor response reflects growing confidence in the company’s clinical and commercial strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au